X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (61) 61
Patent (20) 20
Book / eBook (10) 10
Newspaper Article (4) 4
Book Chapter (3) 3
Publication (3) 3
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22) 22
index medicus (21) 21
chemistry (19) 19
heterocyclic compounds (18) 18
human necessities (18) 18
hygiene (18) 18
medical or veterinary science (18) 18
metallurgy (18) 18
organic chemistry (18) 18
preparations for medical, dental, or toilet purposes (18) 18
female (14) 14
male (13) 13
adult (11) 11
middle aged (11) 11
pharmacology & pharmacy (11) 11
oncology (10) 10
cell line, tumor (9) 9
animals (8) 8
pharmacokinetics (8) 8
research (8) 8
resistance (7) 7
aged (6) 6
analysis (6) 6
cancer (6) 6
chronic myeloid-leukemia (6) 6
imidazoles - pharmacokinetics (6) 6
medicine & public health (6) 6
mice (6) 6
mutation (6) 6
pharmacology/toxicology (6) 6
ponatinib (6) 6
protein kinase inhibitors - pharmacology (6) 6
pyridazines - pharmacokinetics (6) 6
antineoplastic agents - administration & dosage (5) 5
area under curve (5) 5
bcr-abl inhibitor (5) 5
cell proliferation - drug effects (5) 5
dose-response relationship, drug (5) 5
imidazoles - administration & dosage (5) 5
pyridazines - administration & dosage (5) 5
receptor protein-tyrosine kinases - antagonists & inhibitors (5) 5
antineoplastic agents - pharmacokinetics (4) 4
ap24534 (4) 4
cancer research (4) 4
care and treatment (4) 4
cell lung-cancer (4) 4
cross-over studies (4) 4
drug interactions (4) 4
imatinib (4) 4
imidazoles - adverse effects (4) 4
leukemia (4) 4
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (4) 4
mice, scid (4) 4
mutations (4) 4
protein kinase inhibitors - pharmacokinetics (4) 4
pyridazines - adverse effects (4) 4
sirolimus - analogs & derivatives (4) 4
xenograft model antitumor assays (4) 4
administration, oral (3) 3
adolescent (3) 3
anaplastic lymphoma kinase (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - pharmacology (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
cell biology (3) 3
ceritinib (3) 3
chemistry, medicinal (3) 3
chromosome-positive leukemias (3) 3
chronic myeloid leukemia (3) 3
colemanite (3) 3
dosage and administration (3) 3
follow-up studies (3) 3
fusion proteins, bcr-abl - antagonists & inhibitors (3) 3
hemic and lymphatic diseases (3) 3
history (3) 3
imidazoles - pharmacology (3) 3
india (3) 3
inhibitor (3) 3
kinases (3) 3
lung neoplasms - drug therapy (3) 3
lymphomas (3) 3
mammalian target (3) 3
mutant (3) 3
phase-i trial (3) 3
phosphorylation - drug effects (3) 3
potent (3) 3
protein kinase inhibitors - adverse effects (3) 3
pyridazines - pharmacology (3) 3
pyrimidines - pharmacology (3) 3
rats (3) 3
receptor protein-tyrosine kinases - genetics (3) 3
receptor protein-tyrosine kinases - metabolism (3) 3
ridaforolimus (3) 3
sirolimus - administration & dosage (3) 3
statesmen (3) 3
therapy (3) 3
tyrosine (3) 3
tyrosine kinase (3) 3
tyrosine kinase inhibitor (3) 3
young adult (3) 3
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (4) 4
UTL at Downsview - May be requested (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
OISE - Stacks (1) 1
Royal Ontario Museum - Far Eastern (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (98) 98
French (7) 7
German (3) 3
Sanskrit (2) 2
Spanish (2) 2
Chinese (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. 1683 - 1696
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 22, pp. 2075 - 2088
Ponatinib was developed to overcome resistance to the tyrosine kinase inhibitors used to treat leukemias that are positive for the Philadelphia chromosome. In... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | RESPONSE CRITERIA | KINASE DOMAIN MUTATIONS | DIAGNOSED CHRONIC-PHASE | TYROSINE KINASE | INTERNATIONAL-WORKING-GROUP | FOLLOW-UP | CLINICAL RESISTANCE | BCR-ABL INHIBITOR | CHRONIC MYELOID-LEUKEMIA | Amylases - blood | Lipase - blood | Follow-Up Studies | Humans | Middle Aged | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Pyridazines - adverse effects | Imidazoles - adverse effects | Antineoplastic Agents - chemistry | Pancreatitis - chemically induced | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Patient outcomes | BCR-ABL tyrosine kinase inhibitors | Dosage and administration | Genetic aspects | Acute lymphocytic leukemia | Research | Drug therapy | Tyrosine | BCR protein | Acute lymphatic leukemia | Myeloid leukemia | Leukemia | Pancreatitis | Abl protein | Chronic myeloid leukemia | Lymphatic leukemia | Lipase | Kinases | Philadelphia chromosome | Proteins | Myelosuppression | Fusion protein | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 03/2017, Volume 79, Issue 3, p. 507
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00280-017-3240-x A single... 
Tyrosine | Metabolites | Leukemia | Physiological aspects
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5348 - 5348
Abstract Background: ALRN-6924, an α-helical stapled p53 peptide, is the first-in-class and only dual inhibitor of MDMX and MDM2 currently in clinical trials... 
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2016, Volume 59, Issue 10, pp. 4948 - 4964
In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC),... 
CELL LUNG-CANCER | WILD-TYPE | CHEMISTRY, MEDICINAL | SRC TYROSINE KINASE | THERAPEUTIC TARGET | RESISTANCE | ATOMS-IN-MOLECULES | ALK INHIBITOR | IDENTIFICATION | ALK/ROS1 INHIBITOR | SMALL-MOLECULE INHIBITOR | Lung Neoplasms - drug therapy | Phosphines - pharmacology | Humans | Molecular Conformation | Lung Neoplasms - pathology | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Pyrimidines - chemistry | Dose-Response Relationship, Drug | Neoplasms, Experimental - pathology | Protein Kinase Inhibitors - chemistry | Phosphines - chemistry | Organophosphorus Compounds - pharmacology | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Cell Survival - drug effects | Lung Neoplasms - enzymology | Administration, Oral | Pyrimidines - administration & dosage | Rats | Organophosphorus Compounds - chemistry | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Receptor Protein-Tyrosine Kinases - metabolism | Drug Discovery | Protein Kinase Inhibitors - administration & dosage | Animals | Receptor Protein-Tyrosine Kinases - genetics | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Organophosphorus Compounds - administration & dosage | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Neoplasms, Experimental - drug therapy | Drug Screening Assays, Antitumor
Journal Article
Construction and Building Materials, ISSN 0950-0618, 12/2017, Volume 157, pp. 917 - 929
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 06/2010, Volume 53, Issue 12, pp. 4701 - 4719
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 06/2011, Volume 10, Issue 6, pp. 1028 - 1035
Journal Article
Applied Radiation and Isotopes, ISSN 0969-8043, 07/2017, Volume 125, pp. 86 - 93
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2013, Volume 53, Issue 9, pp. 974 - 981
Journal Article
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 08/2019, Volume 8, Issue 6, pp. 734 - 741
Brigatinib, a next‐generation anaplastic lymphoma kinase (ALK) inhibitor, received accelerated approval in the United States for the treatment of patients with... 
brigatinib | Absorption | food effect | non–small‐cell lung cancer | anaplastic lymphoma kinase | non–small-cell lung cancer | MECHANISMS | ALK INHIBITOR | BIOAVAILABILITY | CELL LUNG-CANCER | AP26113 | POTENT | CERITINIB | RESISTANCE | PHARMACOLOGY & PHARMACY | non-small-cell lung cancer | FOOD | Index Medicus | Original Manuscript
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2013, Volume 71, Issue 5, pp. 1315 - 1323
Journal Article